KalVista presents data showing sebetralstat effectiveness in reducing anxiety

KalVista Pharmaceuticals announced that it presented data showing the effectiveness of sebetralstat in reducing anxiety among people experiencing hereditary angioedema attacks at the HAEi Global Angioedema Forum taking place in Copenhagen, Denmark, October 4 – 5, 2024. These data were generated in the KONFIDENT phase 3 clinical trial, for which the company disclosed top line results in February 2024. Sebetralstat is a novel, investigational oral plasma kallikrein inhibitor for the on-demand treatment of HAE attacks in adults and adolescents aged 12 years and older. KONFIDENT was the first randomized controlled trial to assess the impact of an on-demand treatment on anxiety associated with HAE attacks. This prespecified exploratory analysis was presented by Dr. William R. Lumry, AARA Research Center, Dallas, TX, USA and investigated attack-associated anxiety in the phase 3 KONFIDENT trial and the impact of sebetralstat on anxiety, compared with placebo. Participants self-reported anxiety using a Modified Generalized Anxiety Numeric Rating Scale. Overall, anxiety was reduced among patients treated with sebetralstat 300mg and 600mg versus placebo. For participants with moderate-to-extreme anxiety, change from baseline at 4 hours was -2.8 for each sebetralstat group and -1.3 for placebo and at 12 hours was -3.5 with sebetralstat 300mg, -4.3 with 600mg, and -1.7 with placebo. Notably, anxiety reduction was correlated with earlier time to beginning of symptom relief. “The data presented at the Global Angioedema Forum highlights that people living with HAE often experience substantial anxiety when they have attacks, which reduces quality of life. In KONFIDENT, oral sebetralstat significantly reduced anxiety during attacks compared with placebo, especially among participants with moderate-to-extreme anxiety,” said William Lumry, M.D., Allergy and Asthma Research Associates, Dallas, Texas, United States.